Sign In
Buy ATAI
$4.53
-0.280 (-5.82%)
At Close: Jun 03, 2026
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by
Trump Backs Psychedelics. Here's 1 Company Investors Need to Know About
09:50pm, Thursday, 23'rd Apr 2026
Compass Pathways is already in the final stage of development on a psychedelic medicine to treat depression.
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by
FTSE 100 Live: London stocks slide as aerospace and defence sector falls
09:48am, Tuesday, 21'st Apr 2026
FTSE 100 down 35 points at 10,574 Markets await confirmation of US-Iran talks UK bond eyes developments in Westminster AB Foods, British Land,...
Why AtaiBeckley Stock Surged Today
09:51pm, Monday, 20'th Apr 2026
Promising therapies for mental illnesses could see their regulatory reviews quickened. AtaiBeckley is a potential leader in psychedelic treatments.
This 4/20, Wall Street Is Betting on More Than Marijuana
03:05pm, Monday, 20'th Apr 2026
While many investors focused on the annual 4/20 holiday, expecting the usual buzz around marijuana stocks, a quiet revolution was unfolding in Washington. Over a weekend when most of the market was lo
AtaiBeckley Stock Skyrockets After Cantor Fitzgerald's Overweight Rating
02:36pm, Monday, 20'th Apr 2026
AtaiBeckley (NASDAQ: ATAI) shares are surging Monday as psychedelic biotechs rally on President Trump's executive order to fast-track reviews.
AtaiBeckley Stock Skyrockets As Psychedelic Rally Extends On Trump Fast‑Track Order
02:36pm, Monday, 20'th Apr 2026
ATAI surged 28.1% in premarket trading as investors piled into the sector after the administration's weekend directive. The move sparked a broad wave of buying across psychedelic‑focused companies.
How Trump's psychedelics executive order could unlock stalled cannabis reform
02:05pm, Monday, 20'th Apr 2026
The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine. The order does not change their legal status,
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar
11:07am, Monday, 20'th Apr 2026
The FDA will fast-track certain psychedelic treatments. Several biotech stocks are soaring due to the new policy.
Psychedelics stocks rise after Trump order expands research, access pathways
09:59am, Monday, 20'th Apr 2026
Shares of psychedelics-related stocks climbed in early trade on Monday after US president Donald Trump signed an executive order aimed at accelerating research into psychedelic-assisted therapies and
Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.
08:18am, Monday, 20'th Apr 2026
AtaiBeckley and Compass Pathways are two drugmakers developing psychedelic treatments for depression.
Psychedelics stocks rise after Trump order expands research, access pathways
05:56am, Monday, 20'th Apr 2026
Shares of psychedelics-related stocks climbed in early trade on Monday after US president Donald Trump signed an executive order aimed at accelerating...
Silverbullet Data Services shares lifted as it flags 'better than expected' financials
06:07am, Wednesday, 15'th Apr 2026
Silverbullet Data Services Group PLC (LSE:SBDS) saw its shares rise 10.5%, to 21p, after revealing its first period of positive EBITDA, in the first quarter...
Johnson & Johnson's Spravato sales growth signals upside for psychedelics peers like AtaiBeckley
03:22pm, Tuesday, 14'th Apr 2026
Johnson & Johnson (NYSE:JNJ)'s Spravato is reinforcing investor interest in the broader psychedelics sector as it reported another quarter of strong sales growth, with Jefferies analysts pointing to i
